MENY

Gällande vårdprogram

Fastställt av Regionala cancercentrum i samverkan 2019-06-25 korrigerat 2019-10-04

19. Referenser

Abruzzese, E., Trawinska, M. M., Perrotti, A. P., & De Fabritiis, P. (2014). Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis, 6(1), e2014028. doi:10.4084/MJHID.2014.028

Aichberger, K. J., Herndlhofer, S., Agis, H., Sperr, W. R., Esterbauer, H., Rabitsch, W., Valent, P. (2007). Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest, 37(10), 808-813. doi:10.1111/j.1365-2362.2007.01859.x

Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., Marrow Transplant Clinical Trials, N. (2012). Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med, 367(16), 1487-1496. doi:10.1056/NEJMoa1203517

Apperley, J. (2009). CML in pregnancy and childhood. Best Pract Res Clin Haematol, 22(3), 455-474. doi:10.1016/j.beha.2009.09.008

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. doi:10.1182/blood-2016-03-643544

Arora, M., Weisdorf, D. J., Spellman, S. R., Haagenson, M. D., Klein, J. P., Hurley, C. K., Petersdorf, E. W. (2009). HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol, 27(10), 1644-1652. doi:10.1200/JCO.2008.18.7740

Att förebygga aterosklerotisk hjärt-kärlsjukdom med läkemedel – behandlingsrekommendation. Information från Läkemedelsverket 2014;24(5). (2014). Retrieved from https://lakemedelsverket.se/aterosklerotisk_hjart-karlsjukdom

Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F., & Rosti, G. (2014). Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis, 6(1), e2014005. doi:10.4084/MJHID.2014.005

Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122(6), 872-884. doi:10.1182/blood-2013-05-501569

Barber, M. C., Mauro, M. J., & Moslehi, J. (2017). Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program, 2017(1), 110-114. doi:10.1182/asheducation-2017.1.110

Basak, G. W., de Wreede, L. C., van Biezen, A., Wiktor-Jedrzejczak, W., Halaburda, K., Schmid, C., de Witte, T. (2013). Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant, 48(6), 837-842. doi:10.1038/bmt.2012.234

Bennour, A., Bellaaj, H., Ben Youssef, Y., Elloumi, M., Khelif, A., Saad, A., & Sennana, H. (2011). Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. J Cancer Res Clin Oncol, 137(9), 1329-1336. doi:10.1007/s00432-011-1002-4

Bjorkholm, M., Kristinsson, S. Y., Landgren, O., & Goldin, L. R. (2013). No familial aggregation in chronic myeloid leukemia. Blood, 122(3), 460-461. doi:10.1182/blood-2013-05-501312

Bjorkholm, M., Ohm, L., Eloranta, S., Derolf, A., Hultcrantz, M., Sjoberg, J., Dickman, P. W. (2011). Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol, 29(18), 2514-2520. doi:10.1200/JCO.2011.34.7146

Borthakur, G., Verstovsek, S., Jabbour, E., Kadia, T., Daver, N., Kantarjian, H., & Cortes, J. (2013). Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chronic Myeloid Leukemia and Myelofibrosis. . The American Society of Hematology (ASH). 

Branford, S., Melo, J. V., & Hughes, T. P. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood, 114(27), 5426-5435. doi:10.1182/blood-2009-08-215939

Branford, S., Yeung, D. T., Parker, W. T., Roberts, N. D., Purins, L., Braley, J. A., Hughes, T. P. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood, 124(4), 511-518. doi:10.1182/blood-2014-03-566323

Campiotti, L., Suter, M. B., Guasti, L., Piazza, R., Gambacorti-Passerini, C., Grandi, A. M., & Squizzato, A. (2017). Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur J Cancer, 77, 48-56. doi:10.1016/j.ejca.2017.02.028

Common Terminology Criteria for Adverse Events (CTCAE). Retrieved from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50

Cortes, J., Kim, D. W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 22(12), 2176-2183. doi:10.1038/leu.2008.221

Cortes, J., O'Brien, S., Quintas, A., Giles, F., Shan, J., Rios, M. B., Kantarjian, H. (2004). Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer, 100(11), 2396-2402. doi:10.1002/cncr.20292

Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D. W.,  Brummendorf, T. H. (2018). Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol, 36(3), 231-237. doi:10.1200/jco.2017.74.7162

Cortes, J. E., Hochhaus, A., le Coutre, P. D., Rosti, G., Pinilla-Ibarz, J., Jabbour, E.,
Baccarani, M. (2011). Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood, 117(21), 5600-5606. doi:10.1182/blood-2010-11-318949

Cortes, J. E., Kantarjian, H. M., Brummendorf, T. H., Kim, D. W., Turkina, A. G., Shen, Z. X., Gambacorti-Passerini, C. (2011). Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 118(17), 4567-4576. doi:10.1182/blood-2011-05-355594

Cortes, J. E., Khoury, H. J., Kantarjian, H. M., Lipton, J. H., Kim, D. W., Schafhausen, P., Gambacorti-Passerini, C. (2016). Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol, 91(12), 1206-1214. doi:10.1002/ajh.24536

Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Investigators, P. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369(19), 1783-1796. doi:10.1056/NEJMoa1306494

Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boque, C., Hochhaus, A. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 34(20), 2333-2340. doi:10.1200/jco.2015.64.8899

Cortes, J. E., Talpaz, M., & Kantarjian, H. (2014). Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 370(6), 577. doi:10.1056/NEJMc1315234

Cross, N. C. (1998). Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther, 40(5), 224-228. 

Cross, N. C., White, H. E., Colomer, D., Ehrencrona, H., Foroni, L., Gottardi, E., Hochhaus, A. (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. doi:10.1038/leu.2015.29

Cross, N. C., White, H. E., Muller, M. C., Saglio, G., & Hochhaus, A. (2012). Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 26(10), 2172-2175. doi:10.1038/leu.2012.104

Dahlen, T., Edgren, G., Lambe, M., Hoglund, M., Bjorkholm, M., Sandin, F., Stenke, L. (2016). Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. Ann Intern Med, 165(3), 161-166. doi:10.7326/m15-2306

de Lavallade, H., Punnialingam, S., Milojkovic, D., Bua, M., Khorashad, J. S., Gabriel, I. H., Marin, D. (2008). Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol, 141(5), 745-747. doi:10.1111/j.1365-2141.2008.07108.x

Deau, B., Nicolini, F. E., Guilhot, J., Huguet, F., Guerci, A., Legros, L., Rousselot, P. (2011).
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res, 35(6), 777-782. doi:10.1016/j.leukres.2010.11.004

Deininger, M. W., Kopecky, K. J., Radich, J. P., Kamel-Reid, S., Stock, W., Paietta, E.,
Druker, B. J. (2014). Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol, 164(2), 223-232. doi:10.1111/bjh.12618

Eapen, M., Logan, B. R., Confer, D. L., Haagenson, M., Wagner, J. E., Weisdorf, D. J.,
Anasetti, C. (2007). Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant, 13(12), 1461-1468. doi:10.1016/j.bbmt.2007.08.006

Eliasson, L., Clifford, S., Barber, N., & Marin, D. (2011). Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res, 35(5), 626-630. doi:10.1016/j.leukres.2010.10.017

Elsawy, M., & Sorror, M. L. (2016). Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 51(10), 1283-1300. doi:10.1038/bmt.2016.141

Etienne, G., Guilhot, J., Rea, D., Rigal-Huguet, F., Nicolini, F., Charbonnier, A., Mahon, F. X. (2017). Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol, 35(3), 298-305. doi:10.1200/jco.2016.68.2914

Fabarius, A., Leitner, A., Hochhaus, A., Muller, M. C., Hanfstein, B., Haferlach, C., the German, C. M. L. S. G. (2011). Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118(26), 6760-6768. doi:10.1182/blood-2011-08-373902

Fruehauf, S., Topaly, J., Buss, E. C., Fischer, T., Ottmann, O. G., Emmerich, B., Hochhaus, A. (2007). Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 109(8), 1543-1549. doi:10.1002/cncr.22535

Gambacorti-Passerini, C., Brummendorf, T. H., Kim, D. W., Turkina, A. G., Masszi, T., Assouline, S., Cortes, J. E. (2014). Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol, 89(7), 732-742. doi:10.1002/ajh.23728

Gambacorti-Passerini, C., Tornaghi, L., Cavagnini, F., Rossi, P., Pecori-Giraldi, F., Mariani, L., Gnessi, L. (2003). Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet, 361(9373), 1954-1956. doi:10.1016/S0140-6736(03)13554-4

Ghalaut, V. S., Prakash, G., Bansal, P., Dahiya, K., Dokwal, S., Ghalaut, P. S., Dhankhar, R. (2013). Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report. J Oncol Pharm Pract, 20(4), 243-248. doi:10.1177/1078155213500686

Giles, F. J., Kantarjian, H. M., le Coutre, P. D., Baccarani, M., Mahon, F. X., Blakesley, R. E., Ottmann, O. G. (2012). Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia, 26(5), 959-962. doi:10.1038/leu.2011.355

Giles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Kantarjian, H. M. (2013). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 27(1), 107-112. doi:10.1038/leu.2012.181

Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C. E., McNeill, C., Woodman, R. C., Saglio, G. (2013). Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia, 27(6), 1310-1315. doi:10.1038/leu.2013.69

Golas, J. M., Arndt, K., Etienne, C., Lucas, J., Nardin, D., Gibbons, J., Boschelli, F. (2003). SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res, 63(2), 375-381. 

Gratwohl, A. (2012). The EBMT risk score. Bone Marrow Transplant, 47(6), 749-756. doi:10.1038/bmt.2011.110

Gratwohl, A., Brand, R., Apperley, J., Crawley, C., Ruutu, T., Corradini, P., Marrow, T. (2006). Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 91(4), 513-521. 

Gratwohl, A., Stern, M., Brand, R., Apperley, J., Baldomero, H., de Witte, T., the European Leukemia, N. (2009). Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer, 115(20), 4715-4726. doi:10.1002/cncr.24531

Guilhot, F., Coombs, J., Szczudlo, T., Zernovak, O., Paolantonio, M., Bender, C., Shapiro, A. (2013). The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach. Patient, 6(2), 81-92. doi:10.1007/s40271-013-0006-3

Gunnarsson, N., Hoglund, M., Stenke, L., Sandin, F., Bjorkholm, M., Dreimane, A., Sjalander, A. (2017). No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden. Leukemia, 31(8), 1825-1827. doi:10.1038/leu.2017.131

Gunnarsson, N., Sandin, F., Hoglund, M., Stenke, L., Bjorkholm, M., Lambe, M., Sjalander, A. (2016). Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol, 97(4), 387-392. doi:10.1111/ejh.12743

Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Schunemann, H. J. (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 64(4), 383-394. doi:10.1016/j.jclinepi.2010.04.026

Hanfstein, B., Shlyakhto, V., Lauseker, M., Hehlmann, R., Saussele, S., Dietz, C., the German, C. M. L. S. G. (2014). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia, 28(10), 1988-1992. doi:10.1038/leu.2014.153

Haouala, A., Widmer, N., Duchosal, M. A., Montemurro, M., Buclin, T., & Decosterd, L. A. (2011). Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 117(8), e75-87. doi:10.1182/blood-2010-07-294330

Hasford, J., Baccarani, M., Hoffmann, V., Guilhot, J., Saussele, S., Rosti, G., Hehlmann, R. (2011). Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood, 118(3), 686-692. doi:10.1182/blood-2010-12-319038

Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Ansari, H. (1998). A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 90(11), 850-858. 

Hehlmann, R. (2012). How I treat CML blast crisis. Blood, 120(4), 737-747. doi:10.1182/blood-2012-03-380147

Hehlmann, R., Muller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Hochhaus, A. (2014). Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol, 32(5), 415-423. doi:10.1200/JCO.2013.49.9020

Heyssel, R., Brill, A. B., Woodbury, L. A., Nishimura, E. T., Ghose, T., Hoshino, T., & Yamasaki, M. (1960). Leukemia in Hiroshima atomic bomb survivors. Blood, 15, 313-331. 

Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gomez Casares, M. T., Saglio, G. (2017). Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia, 31(7), 1525-1531. doi:10.1038/leu.2017.63

Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Investigators, I. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061. doi:10.1038/leu.2009.38

Hochhaus, A., Saussele, S., Rosti, G., Mahon, F. X., Janssen, J., Hjorth-Hansen, H., Buske, C. (2017). Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28(suppl_4), iv41-iv51. doi:10.1093/annonc/mdx219

Hoglund, M., Sandin, F., Hellstrom, K., Bjoreman, M., Bjorkholm, M., Brune, M., Richter, J. (2013). Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood, 122(7), 1284-1292. doi:10.1182/blood-2013-04-495598

Hoglund, M., Sandin, F., & Simonsson, B. (2015). Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol, 94 Suppl 2, S241-247. doi:10.1007/s00277-015-2314-2

Huang, X., Cortes, J., & Kantarjian, H. (2012). Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 118(12), 3123-3127. doi:10.1002/cncr.26679

Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Goldman, J. M. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1), 28-37. doi:10.1182/blood-2006-01-0092

Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., International Randomised Study of Interferon versus, S. T. I. S. G. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349(15), 1423-1432. doi:10.1056/NEJMoa030513

Hughes, T. P., & Ross, D. M. (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood, 128(1), 17-23. doi:10.1182/blood-2016-01-694265

Ibrahim, A. R., Eliasson, L., Apperley, J. F., Milojkovic, D., Bua, M., Szydlo, R., Marin, D. (2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 117(14), 3733-3736. doi:10.1182/blood-2010-10-309807

Irvine, E., & Williams, C. (2013). Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy, 33(8), 868-881. doi:10.1002/phar.1266

Isobe, Y., Sugimoto, K., Masuda, A., Hamano, Y., & Oshimi, K. (2009). Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J, 39(6), 408-411. doi:10.1111/j.1445-5994.2009.01947.x

Jabbour, E., Deininger, M., & Hochhaus, A. (2011). Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia, 25(2), 201-210. doi:10.1038/leu.2010.215

Jabbour, E., Kantarjian, H., O'Brien, S., Shan, J., Garcia-Manero, G., Wierda, W., Cortes, J. (2011). Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 117(6), 1822-1827. doi:10.1182/blood-2010-07-293977

Jain, P., Kantarjian, H. M., Ghorab, A., Sasaki, K., Jabbour, E. J., Nogueras Gonzalez, G., Cortes, J. E. (2017). Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 123(22), 4391-4402. doi:10.1002/cncr.30864

Jiang, Q., Xu, L. P., Liu, D. H., Liu, K. Y., Chen, S. S., Jiang, B., Huang, X. J. (2011). Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood, 117(11), 3032-3040. doi:10.1182/blood-2010-09-308510

Kaeda, J., O'Shea, D., Szydlo, R. M., Olavarria, E., Dazzi, F., Marin, D., Apperley, J. F. (2006). Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood, 107(10), 4171-4176. doi:10.1182/blood-2005-08-3320

Kalmanti, L., Saussele, S., Lauseker, M., Muller, M. C., Dietz, C. T., Heinrich, L., Hehlmann, R. (2015). Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. doi:10.1038/leu.2015.36

Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Baccarani, M. (2010). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 362(24), 2260-2270. doi:10.1056/NEJMoa1002315

Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., le Coutre, P. D. (2011). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 117(4), 1141-1145. doi:10.1182/blood-2010-03-277152

Kawano, N., Okuda, S., Yoshida, S., Kugimiya, H., Ito, M., Horikawa, N., Kanda, Y. (2011). Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. Int J Hematol, 94(6), 561-566. doi:10.1007/s12185-011-0956-y

Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D. W., Brummendorf, T. H. (2012). Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 119(15), 3403-3412. doi:10.1182/blood-2011-11-390120

Khoury, H. J., Mauro, M. J., Matloub, Y., Chen, T.-T., Bahceci, E., & Deininger, M. (2009). Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). Blood, 114(22), 1128. 

Kim, H. J., Jung, C. W., Kim, K., Ahn, J. S., Kim, W. S., Park, K., Park, K. (2006). Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. J Clin Oncol, 24(24), 4028-4029. doi:10.1200/JCO.2006.05.5608

Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G., le Coutre, P. D. (2013). Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia, 27(6), 1316-1321. doi:10.1038/leu.2013.70

Kronisk Myeloisk Leukemi (KML) - Nationell kvalitetsregisterrapport för 2016. ( , 2017). Retrieved from https://www.cancercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-myelom/kronisk-myeloisk-leukemi-kml/kvalitetsregister/rapporter/

La Rosee, P., Martiat, P., Leitner, A., Klag, T., Muller, M. C., Erben, P., Hochhaus, A. (2013). Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol, 92(10), 1345-1350. doi:10.1007/s00277-013-1769-2

Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W., Kantarjian, H. M. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2197-2203. doi:10.1038/leu.2012.134

Larson, R. A., Kim, D. W., Issaragrilsil, S., Le Coutre, P., Llacer, P. E., Etienne, G., Hughes, T. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. Blood, 124(21), 4541. 

Latagliata, R., Breccia, M., Fava, C., Stagno, F., Tiribelli, M., Luciano, L., Alimena, G. (2013). Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol, 31(2), 103-109. doi:10.1002/hon.2020

Lee, S. E., Choi, S. Y., Kim, S. H., Jang, E. J., Bang, J. H., Byeun, J. Y., Kim, D. W. (2014). Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Hematology, 19(2), 63-72. doi:10.1179/1607845413Y.0000000100

Ljungman, P., Brand, R., Hoek, J., de la Camara, R., Cordonnier, C., Einsele, H., Marrow, T. (2014). Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis, 59(4), 473-481. doi:10.1093/cid/ciu364

Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., de Witte, T., Dini, G., Marrow, T. (2010). Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant, 45(2), 219-234. doi:10.1038/bmt.2009.141

Lubking, A., Dreimane, A., Sandin, F., Isaksson, C., Markevarn, B., Brune, M., Olsson-Stromberg, U. (2019). Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. doi:10.1038/s41409-019-0513-5

Mahon, F. X., Boquimpani, C., Kim, D. W., Benyamini, N., Clementino, N. C. D., Shuvaev, V., Hughes, T. P. (2018). Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med, 168(7), 461-470. doi:10.7326/m17-1094

Mahon, F. X., & Etienne, G. (2014). Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res, 20(2), 310-322. doi:10.1158/1078-0432.CCR-13-1988

Mahon, F. X., Rea, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Intergroupe Francais des Leucemies Myeloides, C. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 11(11), 1029-1035. doi:10.1016/S1470-2045(10)70233-3

Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., Khorashad, J. S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol, 28(14), 2381-2388. doi:10.1200/JCO.2009.26.3087

Marzocchi, G., Castagnetti, F., Luatti, S., Baldazzi, C., Stacchini, M., Gugliotta, G., Gruppo Italiano Malattie, E. d. A. W. P. o. C. M. L. (2011). Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood, 117(25), 6793-6800. doi:10.1182/blood-2011-01-328294

Mathisen, M. S., Kantarjian, H. M., Cortes, J., & Jabbour, E. J. (2014). Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev, 28(5), 179-187. doi:10.1016/j.blre.2014.06.001

Milojkovic, D., Ibrahim, A., Reid, A., Foroni, L., Apperley, J., & Marin, D. (2012). Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica, 97(3), 473-474. doi:10.3324/haematol.2011.057513

Milojkovic, D., Nicholson, E., Apperley, J. F., Holyoake, T. L., Shepherd, P., Drummond, M. W., Marin, D. (2010). Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 95(2), 224-231. doi:10.3324/haematol.2009.012781

Mo, X. D., Jiang, Q., Xu, L. P., Liu, D. H., Liu, K. Y., Jiang, B., Huang, X. J. (2014). Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant, 49(4), 576-580. doi:10.1038/bmt.2013.232

Muller, M. C., Cross, N. C., Erben, P., Schenk, T., Hanfstein, B., Ernst, T., Hochhaus, A. (2009). Harmonization of molecular monitoring of CML therapy in Europe. Leukemia, 23(11), 1957-1963. doi:10.1038/leu.2009.168

Nationellt vårdprogram Palliativ vård i livets slutskede. ( , 2016). Retrieved from https://www.cancercentrum.se/samverkan/vara-uppdrag/palliativ-vard/vardprogram/

Noens, L., van Lierde, M. A., De Bock, R., Verhoef, G., Zachee, P., Berneman, Z., Abraham, I. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 113(22), 5401-5411. doi:10.1182/blood-2008-12-196543

Novotny, J. R., Muller-Beissenhirtz, H., Herget-Rosenthal, S., Kribben, A., & Duhrsen, U. (2005). Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol, 74(6), 501-510. doi:10.1111/j.1600-0609.2005.00421.x

O'Hare, T., Walters, D. K., Deininger, M. W., & Druker, B. J. (2005). AMN107: tightening the grip of imatinib. Cancer Cell, 7(2), 117-119. doi:10.1016/j.ccr.2005.01.020

Ohanian, M., Kantarjian, H. M., Quintas-Cardama, A., Jabbour, E., Abruzzo, L., Verstovsek, S., Cortes, J. E. (2014). Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk, 14(2), 155-162 e151. doi:10.1016/j.clml.2013.08.008

Oyekunle, A., Zander, A. R., Binder, M., Ayuk, F., Zabelina, T., Christopeit, M., Kroger, N. (2013). Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol, 92(4), 487-496. doi:10.1007/s00277-012-1650-8

Palandri, F., Castagnetti, F., Testoni, N., Luatti, S., Marzocchi, G., Bassi, S., Leukemia, G. W. P. o. C. M. (2008). Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica, 93(12), 1792-1796. doi:10.3324/haematol.13068

Pavlu, J., & Apperley, J. F. (2013). Allogeneic stem cell transplantation for chronic myeloid leukemia. Curr Hematol Malig Rep, 8(1), 43-51. doi:10.1007/s11899-012-0149-7

Pavlu, J., Czepulkowski, B., Kaczmarski, R., & Jan-Mohamed, R. (2005). Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. Lancet Oncol, 6(2), 128. doi:10.1016/S1470-2045(05)01744-4

Pfirrmann, M., Baccarani, M., Saussele, S., Guilhot, J., Cervantes, F., Ossenkoppele, G., Simonsson, B. (2016). Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia, 30(1), 48-56. doi:10.1038/leu.2015.261

Pidala, J., Anasetti, C., Kharfan-Dabaja, M. A., Cutler, C., Sheldon, A., & Djulbegovic, B. (2009). Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 15(11), 1415-1421. doi:10.1016/j.bbmt.2009.07.009

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Binno, S. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, 37(29), 2315-2381. doi:10.1093/eurheartj/ehw106

Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., Lee, F. Y. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112(4), 1005-1012. doi:10.1182/blood-2008-02-140665

Pye, S. M., Cortes, J., Ault, P., Hatfield, A., Kantarjian, H., Pilot, R., Apperley, J. F. (2008). The effects of imatinib on pregnancy outcome. Blood, 111(12), 5505-5508. doi:10.1182/blood-2007-10-114900

Quintas-Cardama, A., De Souza Santos, F. P., Kantarjian, H., O'Brien, S., Faderl, S., Awais, A., Cortes, J. (2009). Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer, 115(17), 3935-3943. doi:10.1002/cncr.24432

Quintas-Cardama, A., Kantarjian, H., & Cortes, J. (2012). Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk, 12(5), 337-340. doi:10.1016/j.clml.2012.04.005

Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Garcia-Manero, G., Rios, M. B., Talpaz, M., & Cortes, J. (2004). Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer, 100(12), 2592-2597. doi:10.1002/cncr.20285

Rea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Mahon, F. X. (2017). Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood, 129(7), 846-854. doi:10.1182/blood-2016-09-742205

Remberger, M., Ackefors, M., Berglund, S., Blennow, O., Dahllof, G., Dlugosz, A., Ringden, O. (2011). Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant, 17(11), 1688-1697. doi:10.1016/j.bbmt.2011.05.001

Richter, J., Soderlund, S., Lubking, A., Dreimane, A., Lotfi, K., Markevarn, B., Stenke, L. (2014). Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol, 32(25), 2821-2823. doi:10.1200/jco.2014.55.6910

Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Hughes, T. P. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), 515-522. doi:10.1182/blood-2013-02-483750

Rosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., & Baccarani, M. (2012). Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev, 38(3), 241-248. doi:10.1016/j.ctrv.2011.07.004

Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Mahon, F. X. (2014). Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 32(5), 424-430. doi:10.1200/JCO.2012.48.5797

Santos, F. P., Jones, D., Qiao, W., Cortes, J. E., Ravandi, F., Estey, E. E., Borthakur, G. (2011). Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer, 117(10), 2145-2155. doi:10.1002/cncr.25670

Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., German, C. M. L. S. G. (2010). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 115(10), 1880-1885. doi:10.1182/blood-2009-08-237115

Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Mahon, F. X. (2018). Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol, 19(6), 747-757. doi:10.1016/s1470-2045(18)30192-x

Saussele, S., Richter, J., Hochhaus, A., & Mahon, F. X. (2016). The concept of treatment-free remission in chronic myeloid leukemia. Leukemia, 30(8), 1638-1647. doi:10.1038/leu.2016.115

Savage, D. G., Szydlo, R. M., & Goldman, J. M. (1997). Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol, 96(1), 111-116. 

Schmidt-Hieber, M., Labopin, M., Beelen, D., Volin, L., Ehninger, G., Finke, J., Mohty, M. (2013). CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood, 122(19), 3359-3364. doi:10.1182/blood-2013-05-499830

Schmitz, N., Eapen, M., Horowitz, M. M., Zhang, M. J., Klein, J. P., Rizzo, J. D., Marrow, T. (2006). Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood, 108(13), 4288-4290. doi:10.1182/blood-2006-05-024042

Shah, N. P., Kim, D. W., Kantarjian, H., Rousselot, P., Llacer, P. E., Enrico, A., Hochhaus, A. (2010). Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 95(2), 232-240. doi:10.3324/haematol.2009.011452

Shah, N. P., Rousselot, P., Schiffer, C., Rea, D., Cortes, J. E., Milone, J., Saglio, G. (2016). Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol, 91(9), 869-874. doi:10.1002/ajh.24423

Soderlund, S., Dahlen, T., Sandin, F., Olsson-Stromberg, U., Creignou, M., Dreimane, A., Hoglund, M. (2017). Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register. Eur J Haematol, 98(1), 57-66. doi:10.1111/ejh.12785

Sokal, J. E., Cox, E. B., Baccarani, M., Tura, S., Gomez, G. A., Robertson, J. E., et al. (1984). Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63(4), 789-799. 

Sorror, M., Storer, B., Sandmaier, B. M., Maloney, D. G., Chauncey, T. R., Langston, A., Storb, R. (2008). Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer, 112(9), 1992-2001. doi:10.1002/cncr.23375

Sorror, M. L., Giralt, S., Sandmaier, B. M., De Lima, M., Shahjahan, M., Maloney, D. G., Storb, R. (2007). Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood, 110(13), 4606-4613. doi:10.1182/blood-2007-06-096966

Soverini, S., Branford, S., Nicolini, F. E., Talpaz, M., Deininger, M. W., Martinelli, G., Shah, N. P. (2014). Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res, 38(1), 10-20. doi:10.1016/j.leukres.2013.09.011

Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Martinelli, G. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118(5), 1208-1215. doi:10.1182/blood-2010-12-326405

Strati, P., Kantarjian, H., Thomas, D., O'Brien, S., Konoplev, S., Jorgensen, J. L., Cortes, J. (2014). HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 120(3), 373-380. doi:10.1002/cncr.28433

Tokarski, J. S., Newitt, J. A., Chang, C. Y., Cheng, J. D., Wittekind, M., Kiefer, S. E., Klei, H. E. (2006). The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 66(11), 5790-5797. doi:10.1158/0008-5472.CAN-05-4187

Valent, P., Hadzijusufovic, E., Schernthaner, G. H., Wolf, D., Rea, D., & le Coutre, P. (2015). Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125(6), 901-906. doi:10.1182/blood-2014-09-594432

Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114(5), 937-951. doi:10.1182/blood-2009-03-209262

Warlick, E., Ahn, K. W., Pedersen, T. L., Artz, A., de Lima, M., Pulsipher, M., Weisdorf, D. (2012). Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood, 119(17), 4083-4090. doi:10.1182/blood-2012-02-409763

Verma, D., Kantarjian, H. M., Jones, D., Luthra, R., Borthakur, G., Verstovsek, S., Cortes, J. (2009). Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 114(11), 2232-2235. doi:10.1182/blood-2009-02-204693

Visani, G., Rosti, G., Bandini, G., Tosi, P., Isidori, A., Malagola, M., Tura, S. (2000). Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol, 109(4), 722-728.